Physician profile
Shane J Havens
NPI 1548498447
$6,270.72
in general payments reported to CMS, 2019-2025
21 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $415 · 2020: $162 · 2021: $676 · 2022: $698 · 2023: $2,473 · 2024: $1,204 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,379 · Travel and Lodging: $924 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,379.30 |
| Travel and Lodging | $923.69 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $1,289.99 | 2019-2024 | Radius |
| Abbvie INC. | $955.96 | 2022-2025 | |
| New World Medical,INC. | $716.20 | 2022-2025 | Kahook Dual Blade, Ahmed Glaucoma Valve, Streamline |
| Alcon Vision LLC | $646.37 | 2019-2025 | Hydrus Microstent, Clareon, Rocklatan |
| Bausch & Lomb Americas INC. | $510.13 | 2022-2025 | Vyzulta, Miebo, Xiidra |
| Sun Pharmaceutical Industries INC. | $440.78 | 2020-2025 | Cequa, Xelpros |
| Oyster Point Pharma, INC. | $275.97 | 2022-2024 | Tyrvaya |
| Sight Sciences, INC. | $242.38 | 2019-2024 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $224.01 | 2022-2024 | Omidria, Rayone Spheric, Rayone Emv |
| Allergan, INC. | $200.77 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $178.32 | 2019-2021 | |
| Ivantis, INC | $143.88 | 2021 | |
| Optos, INC. | $107.38 | 2022 | |
| Aerie Pharmaceuticals, INC. | $90.53 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $88.09 | 2019-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $40.77 | 2021-2022 | |
| Lombart Brothers, INC. | $33.86 | 2020 | |
| Harrow Eye, LLC | $28.90 | 2024 | Iheezo |
| Tarsus Pharmaceuticals, INC. | $22.80 | 2024 | Xdemvy |
| Topcon Healthcare, INC. | $18.44 | 2025 | |
| Rxsight INC | $15.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shane Havens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.